Health Affairs, 23, no. 1 (2004): 107-112 doi: 10.1377/hlthaff.23.1.107 © 2004 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (17) Citing Articles via Google Scholar Google Scholar Articles by Reinhardt, U. E. Search for Related Content PubMed PubMed Citation Articles by Reinhardt, U. E. Related Collections Pharmaceuticals Research And Technology

Medicare Challenge

PERSPECTIVE

An Information Infrastructure For The Pharmaceutical Market

The primary contribution of Joseph Newhouse’s paper is to make the point that it is impossible to devise a drug pricing policy that satisfies either the conditions for economic efficiency or prevailing standards of "fairness." Not specifically mentioned by Newhouse is a rule for the socially efficient outlays on selling and marketing by the pharmaceutical industry. In fact, it is not clear that the current allocation of the industry’s revenue dollars to marketing and R&D is efficient from society’s point of view. This paper explores this question and proposes an independent, publicly funded information infrastructure to study and disseminate results on pharmaceutical cost-effectiveness.

                      What's this?

This article has been cited by other articles:

				E. J. Emanuel, V. R. Fuchs, and A. M. Garber Essential Elements of a Technology and Outcomes Assessment Initiative JAMA, September 19, 2007; 298(11): 1323 - 1325. [Full Text] [PDF]

				G. R. Wilensky Developing A Center For Comparative Effectiveness Information Health Aff., November 1, 2006; 25(6): w572 - w585. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry, October 1, 2006; 63(10): 1074 - 1076. [Full Text] [PDF]

				S. R. Tunis and S. D. Pearson Coverage Options For Promising Technologies: Medicare's 'Coverage With Evidence Development' Health Aff., September 1, 2006; 25(5): 1218 - 1230. [Abstract] [Full Text] [PDF]

				U. E. Reinhardt, P. S. Hussey, and G. F. Anderson U.S. Health Care Spending In An International Context Health Aff., May 1, 2004; 23(3): 10 - 25. [Abstract] [Full Text] [PDF]